Search Results for "Antidepressants"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Antidepressants. Results 131 to 140 of 185 total matches.
Onzetra Xsail - Sumatriptan Nasal Powder
The Medical Letter on Drugs and Therapeutics • Jul 18, 2016 (Issue 1499)
inhibitors (SSRIs), serotonin and norepinephrine
reuptake inhibitors (SNRIs), tricyclic antidepressants ...
The FDA has approved Onzetra Xsail (Avanir), a nasal
powder formulation of sumatriptan, for acute treatment
of migraine in adults. Nasal spray formulations of
sumatriptan (Imitrex) and zolmitriptan (Zomig) have
been available for many years.
Fluoxetine (Prozac) and Other Drugs for Treatment of Obesity
The Medical Letter on Drugs and Therapeutics • Nov 25, 1994 (Issue 936)
-hydroxytryptamine) in the central nervous system (CNS). Unlike the tricyclic antidepressants, selective serotonin ...
Recent reports have suggested that some obese patients may benefit from long-term pharmacologic treatment (RL Atkinson and VS Hubbard, Am J Clin Nutr, 60:153, August 1994; DJ Goldstein and JH Potvin, Am J Clin Nutr, 60:647, November 1994). Fluoxetine (Prozac), widely used for treatment of depression and near approval by the US Food and Drug Administration (FDA) for treatment of bulimia, is also being tried for treatment of obesity.
Almotriptan (Axert) and Frovatriptan (Frova) for Migraine
The Medical Letter on Drugs and Therapeutics • Feb 18, 2002 (Issue 1124)
significantly in studies with almotriptan or frovatriptan. The SSRI antidepressant
fluvoxamine (Luvox ...
Almotriptan (Axert - Pharmacia), and Frovatriptan (Frova - Elan) have been approved by the FDA for oral treatment of migraine headache (Drugs of Choice from The Medical Letter 2001, page 131.).
Zolmitriptan (Zomig) Nasal Spray for Migraine
The Medical Letter on Drugs and Therapeutics • Jan 19, 2004 (Issue 1174)
of zolmitriptan. Taking SSRI
antidepressants with triptans has rarely caused serotonin syndrome (weakness ...
Zolmitriptan (Zomig - AstraZeneca) nasal spray was recently approved by the FDA for treatment of migraine. It is the second selective serotonin receptor agonist ("triptan") to become available as a nasal spray; sumatriptan has been available in this form since 1997. Some patients with migraine cannot take tablets because of nausea and vomiting, and nasal sprays are more convenient than subcutaneous injections.
Indacaterol (Arcapta Neohaler) for COPD
The Medical Letter on Drugs and Therapeutics • Apr 30, 2012 (Issue 1389)
use
with MAO inhibitors, tricyclic antidepressants, or other
drugs that prolong the QTc interval ...
The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta2-agonist, for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Indacaterol is not approved for treatment of exacerbations of COPD or for treatment of asthma. It has been available in Europe as Onbrez Breezhaler since 2009.
Drugs That May Cause Psychiatric Symptoms
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008 (Issue 1301)
Antidepressants, tricyclic Mania or hypomania, delirium, hallucinations, Patients with bipolar disorder at highest ...
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Click here to view the free full article.
Click here to view the free full article.
Mibefradil--A New Calcium-Channel Blocker
The Medical Letter on Drugs and Therapeutics • Nov 07, 1997 (Issue 1013)
concentrations increase. Plasma levels of cyclosporine (Sandimmune) and tricyclic antidepressants ...
Mibefradil dihydrochloride (Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as the first T-type calcium-channel blocker for treatment of hypertension and chronic stable angina.
Linezolid (Zyvox)
The Medical Letter on Drugs and Therapeutics • May 29, 2000 (Issue 1079)
and possibly other antidepressants should
be coadministered with caution. Linezolid apparently does not affect ...
Linezolid, the first of a new class of antibiotics, the oxazolidinones, has been marketed for treatment of infection due to vancomycin-resistant Enterococcus faecium, nosocomial and community-acquired pueumonia due to Staphylococcus aureus or penicillin-sucsceptible Streptococcus pneumoniae, and skin and skin structure infections, including those due to methicillin-resistant S. aureus (MRSA).
Alosetron (Lotronex) revisited
The Medical Letter on Drugs and Therapeutics • Aug 05, 2002 (Issue 1136)
such
as hyoscyamine (Levsin, and others), bulking agents such as psyllium, and antidepressants (F
De Ponti and M ...
The FDA recently announced that it will permit reintroduction of alosetron hydrochloride (Lotronex - GlaxoSmithKline) for treatment of irritable bowel syndrome (IBS). The drug was previously withdrawn from the market because of severe gastrointestinal toxicity. The reintroduced drug will have a 50% lower starting dose, a narrower indication and some other marketing restrictions (www.fda.gov/cder/drug/infopage/lotronex/lotronex.htm).
Repetitive Transcranial Magnetic Stimulation (TMS) for Medication-Resistant Depression
The Medical Letter on Drugs and Therapeutics • Feb 09, 2009 (Issue 1305)
) resistant to antidepressant medication. The NeuroStar TMS System
(Neuronetics) produces pulsed magnetic ...
The FDA has cleared a new device for treatment of major depressive disorder (MDD) resistant to antidepressant medication. The NeuroStar TMS System (Neuronetics) produces pulsed magnetic fields that can induce electrical currents in the brain. Unlike electroconvulsive therapy (ECT), it does not require anesthesia or induction of seizures. Other similar devices are under development.